MYOV/PFE—The new data are from an open-label extension study in a phase-3 program that has already had several remarkable successes, so I wouldn't expect the new data to have a big effect on MYOV's share price.
Possible but unlikely, IMO, for the reason mentioned in #msg-160575199.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.